NCT01270698View on ClinicalTrials.gov

Study of IMMU-130 in Patients With Relapsed/Refractory Colorectal Cancer

PHASE1CompletedINTERVENTIONAL

Enrollment

26

Participants

Timeline

Start Date

May 31, 2011

Primary Completion Date

December 31, 2014

Study Completion Date

December 31, 2014

Conditions

Metastatic Colorectal Cancer

Interventions

DRUG

IMMU-130

IMMU-130 will be administered intravenously every 2 weeks for up to 6 months or longer.

Trial Locations (1)

10065

Memorial Sloan-Kettering Cancer Center, New York

Sponsors

Lead Sponsor

Gilead Sciences

All Listed Sponsors

lead

Gilead Sciences

INDUSTRY